Aura Biosciences announced inducement equity awards for its new CEO and President, Natalie Holles, including stock options, restricted stock units (RSUs), and performance-based RSUs (PRSUs). These awards, approved under Nasdaq Listing Rule 5635(c)(4), are designed to incentivize Ms. Holles with vesting schedules tied to her continued service and performance milestones. This move aligns with Aura's strategy to strengthen leadership as it advances its clinical-stage therapies for solid tumors. The inducement grants support the company's growth and innovation goals in oncology treatment development.
BBG Advanced Therapies, part of nonprofit BioBridge Global, has partnered with Kite, a Gilead company, to deploy a Mobile Leukapheresis Center across Texas. This mobile unit collects T-cells from patients locally, reducing travel and logistical chall...
Reference Equity, a shareholder in CBIZ, has called on the company to suspend its share repurchase program and restart its acquisition strategy funded by equity. They argue that while CBIZ shares are undervalued, buybacks do not support strategic gro...
Permutable, a London-based market intelligence company, has joined the TotalEnergiesOn accelerator to develop real-time intelligence solutions for the evolving energy sector, focusing on power and renewables. This six-month program will allow Permuta...
The global nuclear fusion market is projected to grow from $18 billion in 2026 to $33.77 billion by 2031, at a CAGR of 13.4%. This growth is fueled by the global shift toward clean, reliable energy and breakthroughs in fusion technology like inertial...
Onconetix's subsidiary Realbotix partners with Bloom Services to deploy humanoid robots in Northeast England care settings to reduce social isolation among the elderly. The robots provide companionship, cognitive stimulation, and emotional support, s...
